Literature DB >> 2987362

The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B4.

E Wong, R D Camp, M W Greaves.   

Abstract

Topical application of single doses of leukotriene B4, (5-500 ng) under occlusion to the skin of normal volunteers and to the clinically normal skin of patients with untreated stable plaque psoriasis caused an inflammatory reaction lasting several days. Histologically, intraepidermal neutrophil microabscesses were seen in both groups following 50 ng applications of leukotriene B4, but there were significantly fewer intraepidermal neutrophils in the psoriatic than in the normal subjects. Nine repeated daily applications of leukotriene B4 (50 ng) to the same site were associated with a reduction of the visible inflammatory response in both volunteer groups, although application of a single 50 ng dose of leukotriene B4 to an adjacent, previously untreated site at the end of the multiple dose experiments elicited acute erythema and edema. Histologically, there were significantly fewer intraepidermal neutrophils in biopsies from sites to which 9 applications of leukotriene B4 were made than in sites to which 1 dose had been applied at the end of the multiple-dose experiments in both psoriatic and normal volunteers. Therefore, repeated application of leukotriene B4 is associated with decreased responsiveness which is due to a local mechanism in the repeatedly treated skin. No subject developed psoriasis following single or multiple applications of leukotriene B4, suggesting that the production of leukotriene B4 in the epidermis is unlikely to be a primary pathogenic event in this disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987362     DOI: 10.1111/1523-1747.ep12265520

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Cutaneous responses to 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) and 5,12-dihydroxyeicosatetraenoic acid (leukotriene B4) in psoriasis and normal human skin.

Authors:  P M Dowd; A K Black; P W Woollard; M W Greaves
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 2.  Leukotrienes in inflammation.

Authors:  M A Bray
Journal:  Agents Actions       Date:  1986-10

3.  Effects of psoriatic scale extracts on oxidative metabolic responses in granulocytes assessed by chemiluminescence.

Authors:  T Kato; T Terui; H Takematsu; H Tagami
Journal:  Inflammation       Date:  1989-02       Impact factor: 4.092

4.  The chemokinetic response of psoriatic and normal polymorphonuclear leukocytes to arachidonic acid lipoxygenase products.

Authors:  F M Cunningham; E Wong; P M Woollard; M W Greaves
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

5.  Effect of dithranol treatment on arachidonic acid and its lipoxygenase products in psoriasis.

Authors:  R M Barr; E Wong; F M Cunningham; A I Mallet; M W Greaves
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 6.  Leukotriene B4 and platelet-activating factor in human skin.

Authors:  L Michel; L Dubertret
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

7.  The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin.

Authors:  R M Barr; A K Black; P M Dowd; O Koro; K Mistry; J L Isaacs; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

8.  Inhibition of arachidonic acid-induced ear oedema as a model for assessing topical anti-inflammatory compounds.

Authors:  A Crummey; G P Harper; E A Boyle; F R Mangan
Journal:  Agents Actions       Date:  1987-02

Review 9.  Immune surveillance in the skin: mechanisms and clinical consequences.

Authors:  Thomas S Kupper; Robert C Fuhlbrigge
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

10.  Leukotriene Antagonists in Dermatology.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.